西妥昔单抗联合FOLFOXIRI方案治疗不可切除结直肠癌肝转移的临床效果

Abstract
Figure/Table
References (22)
Related Citation (15)

Download: PDF (480 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the clinical effect of Cetuximab combined with FOLFOXIRI regimen in the treatment of liver metastasis of unresectable colorectal cancer. Methods From January 2013 to May 2016, 105 patients with liver metastasis of unresectable colorectal cancer admitted to the Second Affiliated Hospital of Guangzhou University of Chinese Medicine were divided into the control group (52 cases) and the observation group (53 cases) according to the random number table method. The control group was treated with FOLFOXIRI regimen, while the observation group was treated with Cetuximab combined with FOLFOXIRI regimen. 14 days were one chemotherapy cycle. Both groups were given continuous treatment for 4 chemotherapy cycles. The clinical effect was evaluated after treatment. The number and size of lesions and the levels of peripheral blood CD4+, CD8+, CD4+/CD8+, serum glycoantigen 19-9 (CA19-9) and carcinoembryonic antigen (CEA) of patients in two groups were compared between before and after treatment. Survival rates of patients at 6 months, 1 year, and 3 years after treatment were calculated and compared between the two groups. Results The effective rate of the observation group was significantly higher than that of the control group, and the difference was statistically significant (P ＜ 0.05). The number and size of lesions of patients in both groups after treatment were significantly smaller than before treatment, and those in the observation group were significantly smaller than those in the control group, with statistically significant differences (all P ＜ 0.05). The levels of CD4+, CD8+ and CD4+/CD8+ in peripheral blood of patients in the two groups after treatment were significantly higher than those before treatment, and those in the observation group were significantly higher than those in the control group, with statistically significant differences (all P ＜ 0.05). Serum CA19-9 and CEA levels of patients in both groups after treatment were significantly lower than those before treatment, and those in the observation group were significantly lower than those in the control group, with statistically significant differences (all P ＜ 0.05). There was no significant difference in survival rate of patients between the two groups at 6 months after treatment (P ＞ 0.05). The 1 year and 3 year survival rates in the observation group after treatment were significantly higher than those in the control group, with statistically significant differences (all P ＜ 0.05). Conclusion Cetuximab combined with FOLFOXIRI regimen has a significant clinical effect in the treatment of liver metastasis of unresectable colorectal cancer, which can improve the immune function of the body, reduce serum CA19-9 and CEA levels, and prolong the survival time of patients.

Key words： Unresectable colorectal cancer with liver metastasis Cetuximab FOLFOXIRI regimen Curative effect

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LU Ruimin1
	2 LIU Tao2 WANG Xinji2 LI Jianguo2 LIANG Yao3 LUO Lijie1

Cite this article:

LU Ruimin1,2 LIU Tao2 WANG Xinji2 LI Jianguo2 LIANG Yao3 LUO Lijie1. Clinical effect of Cetuximab combined with FOLFOXIRI regimen in the treatment of liver metastasis of unresectable colorectal cancer[J]. 中国医药导报, 2020, 17(5): 95-98,103.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2020/V17/I5/95

[1] 苏晓宇，韩树堂.早期结直肠癌内镜治疗术后中药治疗的辨治规律研究[J].国际中医中药杂志，2018，40（4）：323-326.
[2] 乔大伟，李玉芳，李胜男，等.结直肠癌肝转移动物模型研究进展[J].实验动物科学，2019，36（3）：86-90.
[3] 惠鹏，刘连新，梁英健.结直肠癌肝转移的分子机制研究进展[J].中国普外基础与临床杂志，2019，26（6）：758-763.
[4] 徐国辉，徐宗全，周峥，等.TACE联合贝伐珠单抗治疗不可切除结直肠癌肝转移的临床研究[J].实用癌症杂志，2015，30（10）：1493-1496，1500.
[5] 孙晴，李德川.奥沙利铂或伊立替康联合5-氟尿嘧啶和亚叶酸钙用于不可切除的结直肠癌肝转移术前化疗的比较[J].实用肿瘤杂志，2012，27（4）：424-428.
[6] 尹小五，夏秀梅，鲁斌.西妥昔单抗联合伊立替康治疗转移性结直肠癌的临床观察[J].中国现代医生，2019，57（4）：28-30.
[7] 中华医学会外科学分会胃肠外科学组.结直肠癌肝转移诊断和综合治疗指南（2010）[J].中华胃肠外科杂志，2010， 13（6）：457-470.
[8] 靳剑，王相.XELOX化疗联合中药治疗梗阻性结直肠癌的疗效分析[J].国际中医中药杂志，2016，38（6）：523-526.
[9] 李书有，黄广优，张珍妮，等.阿帕替尼联合FOLFOXIRI方案治疗不可切除结直肠癌肝转移患者的疗效与安全性观察[J].结直肠肛门外科，2019，25（2）：164-167.
[10] 蔡延庆，谢春荣，许宏伟.mFOLFOX-6与FOLFIRI方案治疗转移性结直肠癌的临床疗效比较[J].慢性病学杂志，2019，20（2）：222-224.
[11] 朱方，张全安，郑勤，等.西妥昔单抗联合mFOLFOX6一线治疗k-ras野生型结直肠癌肝转移临床疗效观察[J].中华临床医师杂志：电子版，2013，7（19）：8593-8596.
[12] 王芳，陈随才，曹娜娅，等.伊立替康联合西妥昔单抗对晚期结直肠癌肝转移患者肝功能和组织学的影响[J].中国肿瘤临床与康复，2016，23（9）：1047-1050.
[13] 王晓.射频消融术辅助肝动脉化疗栓塞与西妥昔单抗治疗结直肠癌肝转移临床观察[J].结直肠肛门外科，2018， 24（S2）：157-158.
[14] 李东玲，周京旭，朱茗祺，等.西妥昔单抗和贝伐珠单抗治疗晚期结直肠癌的有效性和安全性比较[J].现代生物医学进展，2019，19（8）：1482-1485.
[15] 周昕，高明娟，陈正权，等.结直肠癌患者术后感染的病原学特点及免疫功能的变化[J].中华医院感染学杂志，2019，29（10）：1531-1534.
[16] 郭玉华.晚期结直肠癌患者接受FOLFOX方案治疗对免疫功能的影响[J].中国社区医师，2018，34（36）：23，25.
[17] 张志国，李文文，杨凡等.SOX联合贝伐单抗和mFOLFOX6联合贝伐单抗方案治疗转移性结直肠癌患者疗效和安全性比较[J].医学综述，2018，24（2）：389-393.
[18] 刘浩聪，雷雨，唐诗，等.西妥昔单抗治疗晚期结直肠癌（mCRC）耐药后复用治疗有效1例报道[J].现代肿瘤医学，2019，27（16）：2946-2949.
[19] 林雪丹，邵建力，杨天兴.糖类抗原19-9对Ⅳ期结直肠癌预后的预测价值[J].中国卫生检验杂志，2019，29（10）：1199-1203.
[20] 黄胜波.结直肠癌患者术前TNM分期与肿瘤指标的关联性分析[J].中国医药科学，2019，9（18）：218-220，241.
[21] 李金娜，张颖，王颖等.不可切除转移性结直肠癌维持治疗的研究进展[J].医学综述，2019，25（7）：1322-1326.
[22] 郭庆伟，徐志诚，崔永欣.结直肠癌术前不同CEA水平对患者预后及复发转移的影响[J].实用癌症杂志，2019， 34（4）：561-563.